Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma. Front Oncol. 2022; 12:1022496.

View in: PubMed